Dasatinib-induced lupus

The Lancet

Volumn 372, Issue 9640, 2008, Pages 713-714

  Rea, Delphine ^a   Bergeron, Anne ^a   Fieschi, Claire ^a   Bengoufa, Djaouida ^a   Oksenhendler, Eric ^a   Dombret, Hervé ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; HYDROXYUREA; NILOTINIB;

AGED; ANAMNESIS; ARTHRALGIA; CANCER RELAPSE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; HEPATOSPLENOMEGALY; HUMAN; LETTER; LUPUS VULGARIS; PRIORITY JOURNAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 50149103984     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61295-7     Document Type: Letter

References (5)

1. Assouline A., Laneuville P., and Gambacorti-Passerini C. Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia. N Engl J Med 354 (2006) 2623-2624
2. Mustjoki S., Laurinolli T., Ekblom M., et al. Clonal large granular lymphocyte expansion associated with dasatinib therapy. Blood 110 (2007) abstr 2938.
3. de Lavallade H., Punnialingam S., Milojkovic D., et al. Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. Br J Haematol 141 (2008) 745-747
4. Crispin J.C., Kyttaris V.C., Juang Y.-T., et al. How signalling and gene transcription aberrations dictate the systemic lupus erythematosus T cell phenotype. Trends Immunol 29 (2008) 110-115
5. Hocchaus A., Kantarjian H.M., Baccarani M., et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukaemia after failure of imatinib therapy. Blood 109 (2007) 2303-2309